Critical findings issued by MHRA

Critical findings issued by MHRA

The MHRA (Medicines and Healthcare Products Regulatory Agency) UK has recently released the annual report of GCP inspection findings from 2016.

A total of 10 commercial sponsors were inspected and there were 3 critical findings from 3 organisations.

Critical finding 1:

At the previous GCP inspection in 2013 there was a critical finding for data integrity relating to the use of electronic patient diaries (EPDs) for trial subjects to record details of IMP administration, any bleeding episodes, and responses to treatment. There were changes to subject-reported data that had been requested by investigator site staff and accepted in the study databases that were not supported by adequate source data. This was a critical finding due to the number of records affected and the direct link between subject-reported data and key study endpoints. In addition, there was a lack of evidence of appropriate testing of EPDs prior to release. This follow up inspection revealed that many of these same issues continued and the critical finding for data integrity remained as the data were unreliable.

Critical finding 2:

A critical finding for data integrity was given for 2 reasons.

Firstly, ineligible subjects were included in the per protocol analysis for 2 trials. This was not in accordance with the definition of the per protocol analysis set defined in ICH E9 ‘Statistical Principles for Clinical Trials’.

Secondly, the audit trail from the Interactive Response Technology (IRT) systems for both trials was not made available during the inspection and when it was provided, there was no time stamp of the actions taken by users. The IRT validation documentation had no evidence that the secondary endpoints scores that were calculated by the IRT system had been validated.

Critical finding 3:

A critical finding was given for essential documents as the Trial Master File (TMF) presented as a hybrid paper and electronic TMF to the inspectors did not meet the requirements of the legislation; i.e., being the basis of the inspection, readily available, directly accessible and complete. The TMF quality generally impeded the inspectors from assessing GCP and legislative compliance. There was a particular issue with product and trial level documents. The TMF issues were seen systematically across all trials selected.

Reference:

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/631254/GCP_INSPECTIONS_METRICS_2015-2016__FINAL_21-07-17_.pdf

No Comments

Sorry, the comment form is closed at this time.

Albert Einstein:
Success = Work + Play
PharmaGCP:
Successful business = Knowledge + Quality
Get in touch with us
info@pharmagcp.com
We work closely with you and carry out research to understand your needs and wishes.